Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Riccardo Ricotta"'
Autor:
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Luca Galli, Giuseppe Fornarini, Paolo Andrea Zucali, Melanie Claps, Silvia Chiellino, Ilaria Zampiva, Stefania Pipitone, Riccardo Ricotta, Mariella Sorarù, Veronica Mollica, Marianna Tudini, Lucia Fratino, Veronica Prati, Orazio Caffo, Francesco Atzori, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Marilena Di Napoli, Andrea Malgeri, Emanuele Naglieri, Alessio Signori, Giuseppe Luigi Banna, Pasquale Rescigno, Linda Cerbone, Lorenzo Antonuzzo, Giandomenico Roviello
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundImmune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role
Externí odkaz:
https://doaj.org/article/e1a5d05c7cd04f7d95a2a3e615d48926
Autor:
Veronica Murianni, Alessio Signori, Sebastiano Buti, Sara Elena Rebuzzi, Davide Bimbatti, Ugo De Giorgi, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Veronica Mollica, Mariella Sorarù, Marianna Tudini, Veronica Prati, Andrea Malgeri, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Massimiliano Spada, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Helga Lipari, Giandomenico Roviello, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundImmunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical p
Externí odkaz:
https://doaj.org/article/00c6e5c2760c42988d637261a6a49e07
Autor:
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Daniele Santini, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Pasquale Rescigno, Sebastiano Buti
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-7 (2022)
Abstract Background Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines and targeted therapy, b
Externí odkaz:
https://doaj.org/article/5d27a41c30724b90858c7fbb9dde10ad
Autor:
Sara Elena Rebuzzi, Alessio Signori, Marco Stellato, Daniele Santini, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Claudia Carella, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Roberto Sabbatini, Riccardo Ricotta, Stefano Panni, Francesco Massari, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Miguel Angel Llaja Obispo, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini, Giuseppe Luigi Banna
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundTreatment choice for metastatic renal cell carcinoma (mRCC) patients is still based on baseline clinical and laboratory factors.MethodsBy a pre-specified analysis of the Meet-URO 15 multicentric retrospective study enrolling 571 pretreated
Externí odkaz:
https://doaj.org/article/371fdc3b51fe41fb93862ce578bbee3e
Autor:
Maria Gemelli, Douglas M. Noonan, Valentina Carlini, Giuseppe Pelosi, Massimo Barberis, Riccardo Ricotta, Adriana Albini
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatments over the last 10 years, with even increasing indications in many neoplasms. Non-small cell lung cancer (NSCLC) is considered highly immunogenic, and ICIs have found a wide set
Externí odkaz:
https://doaj.org/article/8ebc9964a7cf45b79f2a0c6d74c19e6b
Autor:
Nadia Benedetto, Luana Calabrone, Karolina Gutmańska, Nicoletta Macrì, Maria Grazia Cerrito, Riccardo Ricotta, Giuseppe Pelosi, Antonino Bruno, Douglas M. Noonan, Adriana Albini
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Cardiovascular toxicity in cancer patients receiving chemotherapy remains one of the most undesirable side effects, limiting the choice of the most efficient therapeutic regimen, including combinations of different anticancer agents. Anthracyclines (
Externí odkaz:
https://doaj.org/article/8a0d16237ba44942a76f4129f7933f93
Autor:
Maurizia Mello-Grand, Antonino Bruno, Lidia Sacchetto, Simone Cristoni, Ilaria Gregnanin, Alessandro Dematteis, Andrea Zitella, Paolo Gontero, Caterina Peraldo-Neia, Riccardo Ricotta, Douglas M. Noonan, Adriana Albini, Giovanna Chiorino
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Reliable liquid biopsy-based tools able to accurately discriminate prostate cancer (PCa) from benign prostatic hyperplasia (BPH), when PSA is within the “gray zone” (PSA 4–10), are still urgent. We analyzed plasma samples from a cohort of 102 c
Externí odkaz:
https://doaj.org/article/62a2a94d6e1142f6afb3f836b01fc657
Autor:
Valentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, Camillo Porta, Giovanni Pappagallo, Riccardo Ricotta, Giuseppe Procopio
Publikováno v:
Therapeutic Advances in Urology, Vol 13 (2021)
Currently, conventional treatments for metastatic RCC (mRCC) include immune-based combination regimens and/or targeted therapies, the latter mainly acting on angiogenesis, a key element of the process of tumor growth and spread. Although these agents
Externí odkaz:
https://doaj.org/article/fbc12de5f176408cba6c4330cffa1d5f
Autor:
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This m
Externí odkaz:
https://doaj.org/article/b7fbd6a0e95e4fbc8e3f9aaff8b8f0d2
Autor:
Roberta Lombardo, Federica Tosi, Annunziata Nocerino, Katia Bencardino, Valentina Gambi, Riccardo Ricotta, Francesco Spina, Salvatore Siena, Andrea Sartore-Bianchi
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Carcinomas of unknown primary (CUP) account for 3–5% of all malignancy and, despite a reduction in incidence, the overall survival has not improved over the last decade. Chemotherapy regimens have not provided encouraging results. New d
Externí odkaz:
https://doaj.org/article/af225ed6dce0406f9c5dd0982b6623f6